文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

HIV感染对资源有限地区宫颈癌放化疗生存与急性毒性的影响

Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-02-01

在博茨瓦纳开展的前瞻性观察性队列研究,纳入143例接受根治性放化疗的局部晚期宫颈癌患者,其中67%为HIV感染者且均在抗逆转录病毒治疗中。基线血红蛋白>10 g/dL、总放疗剂量≥75 Gy与更好生存相关。

要点

  • HIV感染状态不影响宫颈癌根治性放化疗的2年总生存和急性毒性。
  • 基线血红蛋白>10 g/dL和总放疗剂量≥75 Gy与更好的2年总生存相关。
  • 年龄<40岁较40-59岁与更好的2年总生存相关。

核心结论

  • 在HIV感染得到良好管理的宫颈癌患者中,HIV状态对根治性放化疗的2年总生存和急性毒性无影响。
  • 基线血红蛋白水平、总放疗剂量和年龄与生存相关,且不依赖于HIV状态。

研究设计与样本

  • 前瞻性观察性队列研究,2013年7月至2015年1月在博茨瓦纳纳入143例开始根治性放化疗的局部晚期宫颈癌患者。

主要发现

  • HIV感染与未感染女性的急性毒性无差异。

临床怎么用

  • 对HIV感染得到良好管理的宫颈癌患者,可参照HIV未感染者给予根治性放化疗。
  • 关注基线血红蛋白水平,并尽量实现总放疗剂量≥75 Gy以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively compare survival between human immunodeficiency virus (HIV)-infected versus HIV-uninfected cervical cancer patients who initiated curative chemoradiation therapy (CRT) in a limited-resource setting. METHODS AND MATERIALS: Women with locally advanced cervical cancer with or without HIV infection initiating radical CRT in Botswana were enrolled in a prospective, observational, cohort study from July 2013 through January 2015. RESULTS: Of 182 women treated for cervical cancer during the study period, 143 women initiating curative CRT were included in the study. Eighty-five percent of the participants (122 of 143) had stage II/III cervical cancer, and 67% (96 of 143) were HIV-infected. All HIV-infected patients were receiving antiretroviral therapy (ART) at the time of curative cervical cancer treatment initiation. We found no difference in toxicities between HIV-infected and HIV-uninfected women. The 2-year overall survival (OS) rates were 65% for HIV-infected women (95% confidence interval [CI] 54%-74%) and 66% for HIV-uninfected women (95% CI 49%-79%) (P = .70). Factors associated with better 2-year OS on multivariate analyses included baseline hemoglobin >10 g/dL (hazard ratio [HR] 0.37, 95% CI 0.19-0.72, P = .003), total radiation dose ≥75 Gy (HR 0.52, 95% CI 0.27-0.97, P = .04), and age <40 years versus 40-59 years (HR 2.17, 95% CI 1.05-4.47, P = .03). CONCLUSIONS: Human immunodeficiency virus status had no effect on 2-year OS or on acute toxicities in women with well-managed HIV infection who initiated curative CRT in Botswana. In our cohort, we found that baseline hemoglobin levels, total radiation dose, and age were associated with survival, regardless of HIV status.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Grover S, Bvochora-Nsingo M, Yeager A, et al. Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting. Int J Radiat Oncol Biol Phys. 2018. PMID: 29619965. doi:10.1016/j.ijrobp.2018.01.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。